225. Congenital nephrogenic diabetes insipidus Clinical trials / Disease details
Clinical trials : 15 / Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04939753 (ClinicalTrials.gov) | May 26, 2021 | 27/4/2021 | Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis | Incidence of Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the Intensive Care Unit: a Retrospective Analysis | Nephrogenic Diabetes Insipidus | Drug: Sevoflurane | Universitair Ziekenhuis Brussel | NULL | Recruiting | 18 Years | N/A | All | 1000 | Belgium |